Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of ZD1839 (Iressa®), Trastuzumab (Herceptin®), and Docetaxel (Taxotere®) in Patients With erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma

NCT00086957 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT00086957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00086957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of ZD1839 (Iressa®), Trastuzumab (Herceptin®), and Docetaxel (Taxotere®) in Patients With erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2004
Completion date
August 31, 2015
Enrollment
31 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer